Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | DNIB0600A |
| Trade Name | |
| Synonyms | Lifastuzumab vedotin|RG-7599 |
| Drug Descriptions |
DNIB0600A (Lifastuzumab vedotin) is an antibody-drug conjugate consists of an antibody targeting SLC34A2 and monomethyl auristatin E, which may lead to disruption of the microtubule network in SLC34A2-expressing cancer cells, thereby potentially inhibiting cell proliferation (PMID: 29401246, PMID: 32534811, PMID: 31540980). |
| DrugClasses | |
| CAS Registry Number | 1401812-88-1 |
| NCIT ID | C116747 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + Carboplatin + DNIB0600A | Bevacizumab Carboplatin DNIB0600A | 0 | 1 |
| Carboplatin + DNIB0600A | Carboplatin DNIB0600A | 0 | 1 |
| DNIB0600A | DNIB0600A | 0 | 1 |